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Abstract
It is well known that unrecognized heterogeneity among patients, such as is con-
ferred by genetic subtype, can undermine the power of randomized trial, designed
under the assumption of homogeneity, to detect a truly beneficial treatment. We
consider the conditional power approach to allow for recovery of power under
unexplained heterogeneity. While Proschan and Hunsberger (1995) confined the
application of conditional power design to normally distributed observations, we
consider more general and difficult settings in which the data are in the frame-
work of continuous time and are subject to censoring. In particular, we derive
a procedure appropriate for the analysis of the weighted log rank test under the
assumption of a proportional hazards frailty model. The proposed method is illus-
trated through application to a brain tumor trial.
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1 Introduction
It is well known that unrecognized heterogeneity among patients, such as is conferred by
genetic subtype, can undermine the power of a randomized trial to detect a truly beneficial
treatment (Betensky et al., 2002, Li et al, 2002). One mechanism through which genetic sub-
type might affect study power is that of precision. This operates if treatment is equally effective
in all genetic subtypes, but genetic subtype is itself predictive of survival and not associated
with treatment. The North American and European Intergroup trials comparing chemotherapy
plus radiotherapy versus radiotherapy alone for patients with anaplastic oligodendroglioma, a
type of malignant brain tumor, were designed prior to the discovery of at least three clinically
distinct genetic subtypes among patients with the histological diagnosis of this disease (Ino et
al., 2001). Patients on chemotherapy with allelic loss of chromosome 1p have long survival
times. In contrast, patients on chemotherapy with chromosome 1p intact and no mutation of
the TP53 gene have short survival times. Patients on chemotherapy with chromosome 1p
intact and a TP53 mutation follow an intermediate course. As these genetic subtypes were re-
vealed, the investigators questioned whether the effect of chemotherapy versus radiotherapy
would be attenuated due to failure to adjust for the “precision variable” of genetic subtype.
This scenario illustrates that until all of the genetic underpinings of disease are discovered,
clinical trials will likely suffer from insufficient power due to the as yet unrecognized hetero-
geneity of disease. One partial solution to this problem is to collect specimens from all study
participants for retrospective analysis once the genetics of the disease are understood. Al-
though this will lead to added precision in the analyses, there may not be enough subjects of
certain genetic subtypes for adequately powered analyses. Further, this discovery is unlikely
to occur contemporaneously with the completion of the clinical trial. Also, in many diseases,
unknown environmental influences likewise contribute to heterogeneity and there is even less
direction for the search for these influences.
2
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Another solution is to design clinical trials in recognition of this problem. In the absence of
genetic information to explain subject heterogeneity, a new treatment can be proven effective
only if its average effect among all patients exceeds the average effect of the standard treat-
ment. Typically, the marginalized hazard function for new treatment will not be proportional to
the marginalized hazard for the standard treatment. This is true, for example, if the hazard
function for the new treatment, conditional on an unobserved individual frailty, is proportional
to that for the standard treatment. Another complicating feature is that pilot data may not be re-
flective of population-based data due to inadvertent selection biases (Betensky, et al., 2003).
For these reasons, a trial design based on comparing average treatment effects via the log
rank test, with parameters estimated from pilot data, is likely to be underpowered (Betensky,
et al., 2002). To recover this lost power in the absence of genetic information, we consider a
conditional power design in the setting of the weighted log rank test.
Proschan and Hunsberger (1995) proposed a two-stage design that uses information about
the significance of the treatment effect after the first stage to determine the number of addi-
tional subjects required and the critical value to use after the second stage. In contrast to most
adaptive designs, this procedure uses the first stage to estimate the treatment effect, rather
than the nuisance parameters. Without proper control, the actual type I error rate can be more
than double the originally planned rate. Proschan and Hunsberger (1995) described how to
control this error rate.
While Proschan and Hunsberger (1995) confined their application to normally distributed
observations, adaptive designs have recently aroused much research interest for censored
observations. For example, Schafer and Mueller (2001) and Shen and Cai (2003) have con-
sidered sample size re-estimation for two-stage designs with censored outcomes. However,
virtually no work has been done to accommodate heterogeneities detected at the interim time
points. This paper derives a procedure appropriate for the analysis of the weighted log rank
test under the assumption of a proportional hazards frailty model, where the frailties are intro-
3
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duced to model unobserved heterogeneities. We consider separately two cases of potential
practical interest in the setting of survival data: extension of follow-up time without additional
subject accrual, and extension of follow-up time in conjunction with additional accrual. The
approach selected in practice will depend on the relative costs of additional follow-up time ver-
sus additional subjects. It will depend also on the relative amounts of additional information
expected through each means of extension. That is, if the treatment comparison at the end
of the first stage is not significant, but there is little additional information expected within any
amount of additional follow-up, additional subjects will be required. Although our investigations
of these designs were motivated by the need to recover power in the presence of unrecog-
nized heterogeneity within a proportional hazards frailty model, many of our results hold more
generally for any analysis based on the log rank test.
In Section 2 we present notation and describe the frailty models for unrecognized hetero-
geneity. In Section 3, we derive the conditional power for the weighted log rank test, with
allowance for added follow-up time after the first stage of the study. In Section 4, we describe
the details of the conditional power procedure for added follow-up time. We investigate the
unconditional power of the conditional power procedure in Section 5. In Section 6, we derive
the conditional power for the weighted log rank test, with allowance for both added follow-up
and added subjects after the first stage of the study. We describe the details of this conditional
power procedure in Section 7. We discuss application of the procedures to the frailty model in
Section 8, and we apply the procedure to a brain tumor study in Section 9. Section 10 contains
a discussion of these designs.
2 Frailty proportional hazards model
Suppose each of n subjects, who may enter the study in a ‘staggered entry’ fashion, is ran-
domly assigned to treatment 1 with probability a
1
and to treatment 2 with probability a
2
, leading
to n
1
subjects receiving treatment 1 and n
2
subjects receiving treatment 2. Let Z be the treat-
4
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ment indicator, with Z = 0 for subjects who are assigned treatment 1 and Z = 1 for treatment
2. Associated with each subject is a survival time (measured from study entry), T
i
, and a cen-
soring time, C
i
, distributed according to G, such that G(c) = P (C > c). Only X
i
= min(T
i
; C
i
)
is observed, along with an indicator, Æ
i
, for whether death occurred: Æ
i
= 1 if T
i
 C
i
and Æ
i
= 0
if T
i
> C
i
. Also associated with each subject is an unobserved frailty, b
i
, where b
i
 F (b; ) and
 parameterizes the frailty distribution, F . The frailty captures the unexplained heterogeneity
among subjects (e.g. Oakes, 1989).
We assume that conditional on the unobserved frailty, b, the survival time, T , follows a
proportional hazards model
P (t  T < t+ dtjT  t; Z; b) = 
0
(t) exp(Z + b)dt: (1)
Here,  measures the main effect for treatment. We also assume that this conditional propor-
tional hazards model will be valid throughout the study period; similar proportionality assump-
tions have been made in other conditional power literatures (see, e.g. Betensky (1998)). In
general, the unconditional treatment-specific hazard functions induced from (1) do not follow a
proportional hazards model (Betensky, et al, 2002). An exception is the positive stable frailty
model, which preserves the marginal proportionality (Hougaard, 1986).
Under model (1), the marginal cumulative hazard function for the Z = 1 group is
(tj) =   log(Pf

(t)g)
and the hazard function is
(tj) =  
d
dt
log(Pf

(t)g) = 
0
(t) exp()
 P
0
f

(t)g
Pf

(t)g
;
where 

(t) = 
0
(t) exp(), 
0
(t) =
R
t
0

0
(s)ds, and P (s) =
R
e
 s exp(b)
dF (b; ) is the Laplace
transform for the random variable exp(b). The marginal cumulative hazard function and haz-
ard function for the Z = 0 group are denoted by (tj0) and (tj0), respectively. Assuming
5
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differentiability of (tj) with respect to  in a neighborhood of 0, a Taylor series expansion
yields
(tj)
:
= (tj0) + 
@
@
j
=0
(tj):
While in our motivating brain tumor example we considered the case of three genetic sub-
types, in reality we expect subjects’ complete genetic profiles to confer continua of risk. Thus,
we consider the frailty to be a continuous random variable. When the frailty, b, follows certain
common distributions, closed-form expressions for the Laplace transform function P (s) are
available:
1. normal frailty:
P (s) =
Z
1
 1
exp( se
p
x
)(x)dx;
2. log gamma frailty:
P (s) = (1 + s)
 1=
;
3. inverse Gaussian frailty (Hougaard, 1984)
P (s) = expf [(1 + 2s)
1=2
  1]g;
4. positive stable (Hougaard, 1986)
P (s) = exp( s

):
In each of these,  > 0 is the variance of the frailty. When the frailty follows one of these
distributions, (tj) increases with  for fixed t.
3 Weighted log rank test and conditional power for adding follow-
up
In this section, we compute the conditional power for the weighted log rank test. Many compo-
nents of these results, and those of Sections 4-7, are completely general and are not confined
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to any specific model, such as the frailty models of Section 2. In Sections 8 and 9 we discuss
application of this procedure to data that follow the frailty models of Section 2.
The log rank test can be written in the following general form:
L(t) =
Z
t
0
K(u)
d

N
1
(u)

Y
1
(u)
 
Z
t
0
K(u)
d

N
2
(u)

Y
2
(u)
; (2)
where, for k = 1; 2, the total number of subjects at risk in each treatment group at time t is

Y
k
(t) =
P
n
i=1
Y
i
(t)I(Z
i
= k  1), the total number of observed failures in each treatment group
by t is N
k
(t) =
P
n
i=1
N
i
(t)I(Z
i
= k   1), and
K(s) = w(s)

n
1
+ n
2
n
1
n
2

1=2

Y
1

Y
2

Y
1
+

Y
2
;
where w(s) is a predicatable weight function. Commonly used weight functions can be found
in Fleming and Harrington (p.257, 1991). In particular, w(s)  1 corresponds to the simple log
rank test.
Under a sequence of local alternatives for  that converges to zero at the appropriate rate
as the sample size increases to infinity, the log rank statistic has asymptotically a finite mean
and variance. In particular, we have the following asymptotic result.
Proposition 1 Assume that for each k = 1; 2, there exists a function 
k
and a constant a
k
such that
sup
t0





Y
k
(t)
n
k
  
k
(t)




p
! 0 (3)
and
n
k
n
! a
k
: (4)
Assume further that, under a sequence of local alternatives converging to null at the rate of
n
 1=2
, say, 
n
= [(n
1
+ n
2
)=(n
1
n
2
)]
1=2

0
,
sup
t>0




(tj
n
)  (tj0)




! 0: (5)
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Then, as n ! 1, on any finite interval, [0;  ], where  < 
0
= supft > 0 : 
1
(t)
2
(t) > 0g, the
weighted log rank test L() converges weakly to a tight Gaussian process L1(), which takes
form
L
1
(t) = (t) +Bfv(t)g;
where Bftg is a standard Brownian motion, drift
(t) =
Z
t
0
(u)(u)d(uj
0
);
and variance function
v(t) =
Z
t
0
a
1

1
(u) + a
2

2
(u)

1
(u)
2
(u)

2
(u)d(uj
0
):
Here (t) is the probabilistic limit of f(n
1
+ n
2
)=(n
1
n
2
)g
1=2
K(t), and (t) is the probabilistic
limit of f(n
1
n
2
)=(n
1
+ n
2
)g
1=2
n
(tj
0
)
(tj0)
  1
o
.
This proposition is a direct application of Theorem 7.4.1 in Fleming and Harrington (1991,
p.269) after verifying that their conditions (4.5)-(4.8) hold on any finite interval [0;  ]. From this
proposition, it follows that L1(t) has mean function (t), variance function v(t), and covariance
function CovfL1(t); L1(s)g = vfmin(s; t)g. Some algebra shows that
(u) =
w(u)
1
(u)
2
(u)
a
1

1
(u) + a
2

2
(u)
;
and, hence,
v(t) =
Z
t
0
w
2
(u)

1
(u)
2
(u)
a
1

1
(u) + a
2

2
(u)
d(uj0) =
Z
t
0
w(u)(u)d(uj0):
Note that when  > 0, (u) > 0 since (tj) > (tj0) under the frailty model. This implies that
(t) increases with t when  > 0. This, of course, is not the case for all applications of the
weighted log rank test, but is particular to the frailty model (1).
At a pre-determined time t
1
(e.g. interim analysis time), the normalized test statistic is
given by
l
t
1
= L(t
1
)=v^
1=2
(t
1
);
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where v^() is obtained from v() by replacing  with ^. It follows from Proposition 1 that
CP

0
(t; z

jl
t
1
), the conditional probability that the normalized test statistic at time t, L(t)=v^1=2(t),
will exceed z

, given the value of the statistic at time t
1
and given that 
n
= (n
1
+n
2
=n
1
n
2
)
1=2

0
is
CP

0
(t; z

jl
t
1
) = P

L(t)
v^
1=2
(t)
> z





L(t
1
)
v^
1=2
(t
1
)
= l
t
1
; 
0

:
= P

L
1
(t)
v
1=2
(t)
> z





L
1
(t
1
)
v
1=2
(t
1
)
= l
t
1
; 
0

= P

L
1
(t)  L
1
(t
1
) + L
1
(t
1
)
v
1=2
(t)
> z





L
1
(t
1
)
v
1=2
(t
1
)
= l
t
1
; 
0

= P

L
1
(t)  L
1
(t
1
) > z

v
1=2
(t)  l
t
1
v
1=2
(t
1
)





0

= P

L
1
(t)  L
1
(t
1
)  f(t)  (t
1
)g
fv(t)  v(t
1
)g
1=2
>
z

v
1=2
(t)  l
t
1
v
1=2
(t
1
)  f(t)  (t
1
)g
fv(t)  v(t
1
)g
1=2





0
!
:
The := above stems from the weak convergence of L() to L1() and the last two equalities
follow from the independent increment property for a Brownian motion. Hence,
CP

0
(t; z

jl
t
1
)
:
= 1  
 
z

v
1=2
(t)  l
t
1
v
1=2
(t
1
)  [(t)  (t
1
)]
[v(t)  v(t
1
)]
1=2
!
; (6)
where () is the cdf for a standard normal distribution.
4 Designed extension via conditional power: adding follow-up
In this section, we propose an extension of the two-stage design of Proschan and Hunsberger
(1995) to the weighted log rank test, with possible extension of follow-up time. The key idea
behind this methodology is to, based on the data of the first stage, determine the type I error
level to use at the second stage, and then apply a logrank test at this level to events occurring
in the second stage, while maintaining the overall type I error at a prescribed level (say, 0.05).
Specifically, at the time of the interim analysis, t
1
, we calculate the additional follow-up time,
t   t
1
, and the critical value, z

, such that the conditional power, CP

0
(t; z

jl
t
1
) = 1   Æ. The
9
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type I error rate for this design is
Z
1
 1
CP
0
(t; z

jl
t
1
)(l
t
1
)dl
t
1
where () is the standard normal density.
If t is chosen without regard to controlling the overall type I error rate, it can far exceed the
nominal  level. To see this, consider choosing t to maximize the null conditional power
CP
0
(t; z

jl
t
1
) = P
0

L(t)
p
v(t)
> z





L(t
1
)
p
v(t
1
)
= l
t
1

= 1  

z

p
v(t)  l
t
1
p
v(t
1
)
p
v(t)  v(t
1
)

:
When l
t
1
> z

, t = t
1
is the maximizer, with CP
0
= 1. Otherwise CP
0
(t; z

jl
t
1
) = 1  
((z

p
1 +R   l
t
1
)=
p
R), where R = v(t)=v(t
1
)   1 is the additional information (expected
events) when the study is extended to time t, expressed as multiples of the information avail-
able at interim t
1
. Denote by R
max
= v(1)=v(t
1
)  1 the maximum additional information that
could be added. Following Proschan and Hunsberger (1995), we obtain the maximum type I
error rate, 
max
, which is

max
=
Z
0
 1
"
1  

z

p
1 +R
max
  l
t
1
p
R
max

#
(l
t
1
)dl
t
1
+
Z
z

p
1+R
max
0
"
1  

z

p
1 +R
max
  l
t
1
p
R
max

#
(l
t
1
)dl
t
1
+
Z
z

z

p
1+R
max
"
1  

q
z
2

  l
2
t
1

#
(l
t
1
)dl
t
1
+
Z
1
z

(l
t
1
)dl
t
1
: (7)
When R
max
= 1, this expression (7) reduces to expression (A1) of Proschan and Huns-
berger (1995). For significance level  = 0:05 with z

= 1:645, Table 1 lists the maximum type
I error, 
max
, for a range of R
max
.
This inflation of the type I error can be avoided by using a larger critical value k > z

(at
stages 1 and 2) and not continuing the study unless the p-value at time t
1
is less than some
number p, where p  0:5. In this case, the maximum type I error is 
max
=
R
1
 1
A
0
(l
t
1
)(l
t
1
) dl
t
1
,
10
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where
A
0
(l
t
1
) =
8
>
>
>
<
>
>
:
0 if l
t
1
< z
p

1  

k
p
1+R
max
 l
t
1
p
R
max

if z
p

 l
t
1
< max(z
p

;
k
p
1+R
max
)
1  

q
k
2
  l
2
t
1

if max(z
p

;
k
p
1+R
max
)  l
t
1
< k
1 if l
t
1
 k:
For a given R
max
= v(1)=v(t
1
)   1, we choose p and k such that
R
1
 1
A
0
(z
1
)(z
1
) dz
1
= .
This conditional error function contains both “circular” and “linear” components (Proschan and
Hunsberger, 1995). Table 2 lists the values of k corresponding to different choices of p and
R
max
for  = 0:05. As expected, k increases with respect to both p and R
max
.
This maximal error function is one example of an increasing function with range [0; 1],
A(l
t
1
), that satisfies the type I error requirement,
R
1
 1
A(l
t
1
)(l
t
1
)dl
t
1
= . The general con-
ditional power procedure proposed by Proschan and Hunsberger (1995) can be defined with
respect to any such function, A(l
t
1
). For example, one advantage to a linear conditional error
function is that if extension of the trial is unnecessary, the test at the end is the same as it
would be for a fixed sample test. Now we consider the choice of t based on any such function.
Setting CP
0
(t; c(t)jl
t
1
) = A(l
t
1
) and solving for c(t) yields
c(t) =
p
v(t
1
)l
t
1
+
p
v(t)  v(t
1
)z
A
p
v(t)
=
l
t
1
+
p
Rz
A
p
1 +R
; (8)
where z
A
= z
A(l
t
1
)
and R = v(t)=v(t
1
)  1. Note that however we choose t, if the critical point
c is chosen to satisfy (8), then we have an -level procedure. In particular, we may choose t
such that the conditional power under the alternative is large, e.g. CP

(t; cjz
1
) = 1 Æ: Plugging
(8) in the expression for CP

(t; cjz
1
) yields
CP

(t; cjz
1
) = 1  

z
A
 
(t)  (t
1
)
p
v(t)  v(t
1
)

= 1  Æ:
Therefore, it is possible to achieve conditional power 1   Æ at time t if there exists a value t
such that
z
A
+ z
Æ
=
(t)  (t
1
)
p
v(t)  v(t
1
)
: (9)
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As noted in Section 2, a solution does exist in the context of proportional hazards frailty models
with many common frailty distributions, as in these cases (t) is increasing in t.
5 Comparison to single stage test
Although the two-stage procedure is designed to achieve a certain level of conditional power, in
many applications unconditional power is important as well. We conducted a simulation study
to investigate the unconditional power properties of this design. Specifically, we assumed
the proportional hazards gamma frailty model (1) for n = 100 subjects, assigned with equal
probability to each treatment, with 
0
(t) = 1,  = 0:8, and with frailty distributed according
to a log gamma, Gaussian, or inverse Gaussian distribution with variance  = 0:3 or 0:8. We
examined R
max
= 0:50; 1:5; 5:0, conditional power threshold 1   Æ = 0:5; 0:8, and we took
p

= 0:15. For each parameter configuration and R
max
, we calculated the time of the first
analysis, t
1
, to satisfy v(1)=v(t
1
)  1 = R
max
, and the time for the final analysis, t, to achieve
conditional power 1 Æ. Presented in Tables 3 and 4 are the type I error rates for this two-stage
procedure and the unconditional power at times t
1
and t, estimated based on 5000 repetitions.
Also given in Table 4 is the proportional increase in follow-up time required to achieve the given
conditional power. For comparison, all of these quantities are also given in Table 4 when the
no-frailty model is used for analysis.
Table 3 illustrates that the type I error is preserved under misspecification of the frailty
distribution. It is not surprising that there is increased power under the two-stage design, as
seen in Table 4, under correct specification of the log gamma frailty distribution. What is of
interest is the varying costs, in terms of additional follow-up time, of the increased power.
When the power of the fixed sample test is high, as it is at  = 0:3 and R
max
= 0:5, the follow-
up time is increased by less than 5% to achieve the specified conditional power thresholds. In
contrast, when the power of the fixed sample test is low, as it is at  = 0:8 and R
max
= 5:0,
a 50% increase in follow-up time accompanies an increase in power from 36% to 50%. Also
12
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of note is the limitation of this procedure; by adding follow-up time without adding subjects,
the unconditional power may be bounded well below one. The results in Table 4 suggest that
the assumption of the gamma frailty model is robust to misspecification, as the unconditional
power remains high even when the frailty is truly normal or inverse Gaussian. However, the
omission of the frailty from the model leads to a small, but consistent, decrease in unconditional
power.
6 Weighted log rank test and conditional power for adding follow-
up and subjects
We now consider the situation in which additional subjects may be added after the first stage
of the trial. Formally, suppose that after the interim time point t
1
, n
0 new subjects are enrolled,
possibly in a staggered entry fashion, with n0
1
and n0
2
patients assigned to treatments 1 and
2, respectively, with the same randomization probabilities as from stage 1, a
1
and a
2
. For
k = 1; 2, let Y 0
k
(t) =
P
n+n
0
i=n+1
Y
i
(t)I(Z
i
= k   1) denote the total number of subjects at risk
at calendar time t + t
1
among the newly added patients within each treatment arm , and

N
0
k
(t) =
P
n+n
0
i=n+1
N
i
(t)I(Z
i
= k   1), the total number of subjects who have failed by calendar
time t+ t
1
among the newly added patients, within each treatment arm.
The weighted log rank test, with t
2
units of additional follow-up time beyond the interim time
point t
1
(t
1
+ t
2
< 
0
) and n0 subjects added after the interim time t
1
, can be expressed as
~
L
t
1
(t
2
) =
Z
t
1
+t
2
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~
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d
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2
(u)
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2
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2
)

Y
2
0
(u)
;
(10)
with normalizing predictable process
~
K(u) = w(u)

n
1
+ n
0
1
I(u  t
2
) + n
2
+ n
0
2
I(u  t
2
)
[n
1
+ n
0
1
I(u  t
2
)][n
2
+ n
0
2
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2
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(
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Y
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+
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Y
1
0
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))(
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Y
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+

Y
2
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2
))

Y
1
+

Y
1
0
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2
) +

Y
2
+

Y
2
0
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2
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:
Note that when t
2
= 0 or n0 = 0, the modified log rank test (10) reduces to the original test (2).
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To calculate the conditional power of this test, the asymptotic distribution of (~L
t
1
(0);
~
L
t
1
(t
2
)) =
(L(t
1
);
~
L
t
1
(t
2
)) is required. For notational simplicity, let ~(u) denote the probabilistic limit of
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and let ~(u) denote the probabilistic limit of
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
(uj)
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Further, define
~(t) =
Z
t
0
~(u)~(u)d(u):
Using Martingale theory, we prove the following Proposition in the Appendix:
Proposition 2 In addition to the assumptions of Proposition 1, assume further that for each
k = 1; 2,
sup
t0





Y
0
k
(t)
n
0
k
  
0
k
(t)




p
! 0 (13)
and there exists a positive constant r such that
n
0
k
n
k
! r: (14)
Then as n!1, under the local alternatives,
(L(t
1
);
~
L
t
1
(t
2
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D
! (L
1
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);
where (L1
1
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R
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;
and ~v() is given in the Appendix.
Under assumptions (13) and (14), ~(u) = (u) and
~(u) =
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We note that the scientific interpretation of the weighted log rank test changes also over
time. With a change in the censoring distribution over the course of the interim analyses, the
weighting used to compare the hazards changes. Therefore, under the proportional hazards
frailty model, the test statistics are changing functionals of the underlying distribution function
(of time to event and time to censoring).
7 Designed extension via conditional power: adding follow-up
and subjects
Assuming further that r = n0=n and recalling that v(s) =
R
s
0
w
2
(u)
1
(u)
2
(u)
a
1

1
(u)+a
2

2
(u)
du, it follows from
Proposition 2 that
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)) 
(
1
p
r+1
v(t
1
) if t
2
> t
1
1
p
r+1
v(t
2
) 
h
v(t
2
)  v(t
1
)
i
if 0  t
2
 t
1
:
(16)
Therefore, when the conditional power function is a function of both additional follow-up, t
2
and
proportion of original subjects to be added, r, it follows that
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mum 1  (
q
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Therefore, the maximum type I error for weighted log rank test that adds both follow-up and
subjects is 
max
= +exp( z
2

=2)=4, as in Proschan and Hunsburger’s (1995) simple scenario
of testing normal means. Also, when using a larger critical value k > z

and not continuing the
study for l
t
1
< z
p
 for some p  0:5, the maximum type I error is 
max
=
R
1
 1
A
cir
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1
)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1
) dz
1
,
where A
cir
() is as defined in equation (2) of Proschan and Hunsburger (1995).
This maximal error function is one example of a function, A(l
t
1
). The conditional power
procedure is most generally defined with respect to any such function, A(l
t
1
). Now we consider
the choice of t
2
and r based on any such function. Setting CP
0
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; r; cjl
t
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) = A(l
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However we choose (t
2
; r), the type I error is  as long as the critical value c(t
2
; r) is chosen to
satisfy (17). In particular, we may choose (t
2
; r) such that CP

(t
2
; r; cjl
t
1
) = 1 Æ. Plugging (17)
into the expression for CP

(t
2
; r; cjl
t
1
), it follows that this conditional power can be achieved by
any (t
2
; r) such that
z
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=
~(t
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)
p
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)  
2
v(t
1
)
;
where z
A
= z
A(l
t
1
)
. Note that this reduces to (9) when new subjects are not added (i.e., when
r = 0 and therefore  = 1).
8 Application to frailty model
Although motivated by the problem of heterogeneity in randomized trials, many components
of the results presented in Sections 3–7 are applicable to any situation in which the weighted
log rank test is used for analysis. For application of the conditional power procedure, a model
must be assumed for the data and the unknown parameters of the model must be known.
The analysis at t
1
can typically be used to estimate these parameters. For the frailty model,
these include the baseline hazard function and the frailty variance parameter, . Although 
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is not identifiable in the absence of additional data (at least in the presence of a binary treat-
ment indicator), in many situations it may be reasonable to assume that there is a secondary
endpoint that shares the frailty with the endpoint of interest (Oakes, 1989). In this case,  is es-
timable from the marginal association of the two events. For example, for a log gamma frailty,
 = 1=2   1, where  is Kendall’s tau measure of association between the two events. Thus,
a simple nonparametric estimate of  is available at the stage 1 analysis that does not depend
on the joint survivor distribution of the two events. If one of the endpoints is death, and thus
the event times are ordered, the work of Jiang, et al (1999) is applicable. Of potential concern
is the variability with the measure of association is estimated, especially at a relatively early
point in the study. However  is estimated, it must be done so consistently so that Slutsky’s
Theorem can be invoked. We recommend a sensitivity analysis with respect to , informed by
the estimated measure of association.
9 Brain tumor example
To illustrate the proposed design, we use an expanded version of a brain tumor data set an-
alyzed in Ino, et al. (2001). Patients in this study were diagnosed with anaplastic oligoden-
droglioma, a common variant of malignant brain tumor. Ninety-six subjects were enrolled in
the study, and 49 of them died during the study period. Loss of Heterozygosity (LOH) of chro-
mosome 1p was found to be highly predictive of survival among these patients. For illustration,
we consider the problem of testing whether LOH at chromosome 19q is predictive of survival
when ignoring LOH at 1p; that is, we pretend that the biologists had not yet discovered that 1p
LOH is predictive of survival and thus artificially ensure that there is important unrecognized
heterogeneity in the data. Indeed in this study a number of subjects were missing the covariate
of 1p LOH.
We consider what would have happened if the study had been conducted in two stages,
the first being at t
1
= 185 months. For simplicity, we assume that the frailty, b, induced by
17
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ignoring LOH at 1p, has a known variance ^ = 0:571. We used p^(1   p^)^2 to estimate this
variance, where p^ is the proportion of subjects with 1p LOH, which is estimated based on
subjects with complete 1p LOH information, and ^ is the estimated coefficient for 1p LOH
in a proportional hazards model with covariates 1p LOH and 19q LOH among subjects with
complete 1p LOH and 19q LOH information. To account for the variability of the estimated
frailty parameter, we propose below a sensitivity analysis to examine the choice of ^. This
sensitivity analysis approach is immediately available to the analysis of real data for which we
suspect heterogeneity but the magnitude of such heterogeneity is uncertain.
At t
1
= 185 months, 66 subjects had entered the study: 54 of them (with 16 deaths) had
19q LOH and 12 of them (with 4 deaths) did not have 19q LOH. The fitted cumulative hazard
functions with a Weibull baseline hazard are shown in Figure 1 for the four parametric frailty
models considered in Section 2. Also shown in Figure 1 are the nonparametric estimates of the
cumulative hazard functions (dotted lines). All frailty models provide a reasonably good fit, with
the fit under the positive stable model worse than the other three. The positive stable model
yields proportional marginal hazard functions and thus does not capture the nonproportional
marginal hazards observed in this dataset.
For illustration, we carried out the conditional power calculation for the weighted log rank
test. Under the normal frailty model, the optimally weighted log rank statistic is L(t1)p
v(t
1
)
=
 1:516, with one-sided p-value 0:065. The optimal weight is defined to maximize the Pitman
asymptotic efficacy defined in (4.11) of Fleming and Harrington (p.270, 1991). The variance
function, v(t
1
), is calculated under the assumed parametric model,
(tjLOH19q; b) = 
0
t
p 1
exp(  1
fLOH19q=1g
+ b);
where the frailty b follows a normal distribution with mean 0 and variance 0:571. The maximum
likelihood estimates for 
0
, p and  are 4:23 10 4, 2:244, and  2:525, respectively. It follows
that R
max
= 0:441. For p = 0:15, we have k = 1:770 for r = 0 and the conditional error
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function derived in Section 4 and we have k = 1:821 for r > 0 and the circular conditional error
function, A
cir
(Section 7). Figure 2(a) displays the conditional power for extending follow-up
time by 6 to 36 months and adding r times as many new subjects, assuming that 80% of the
new subjects enter the study uniformly during the first one-third of the follow-up period and the
other 20% of new subjects enter the study uniformly during the last two-thirds of the follow-up
period. It is clear that extending follow-up alone will not yield high conditional power, as can
be expected from moderate R
max
. To attain 80% conditional power, one can either add half
as many subjects (r = 0:5) and extend the follow-up by 27.4 months, add as many subjects
(r = 1) and extend the follow-up by 22.6 months, or add twice as many subjects (r = 2) and
extend the follow-up by 18.6 months. Also shown in Figure 2 are the conditional power of the
weighted log rank test under log gamma, inverse Gaussian, and positive stable frailty models.
The conditional powers for the log gamma and inverse Gaussian frailty model are similar to
that for a normal frailty model. For example, to obtain 80% conditional power with as many new
subjects, it requires extending follow-up by 22.9 months under a log gamma frailty model and
24.7 under an inverse Gaussian frailty model, as compared to 22.9 months under a normal
frailty model. For the not as well fitted positive stable frailty model, it requires 27.0 months
of additional follow-up. These results suggest that the designed extension using conditional
power is robust to the selected frailty model, as long as the chosen frailty model provides a
reasonable fit to data.
We went through this same exercise for the simple log rank statistic. With adding as many
new subjects (r = 1), the required follow-up for the normal, log gamma, inverse Gaussian and
positive stable frailty models are 29.6, 34.4, 34.2, and 27.0 months, respectively; all of them
are longer than those for the weighted log rank statistic. This suggests that in spite of the
added computational burden of computing the optimal weights, the weighted test is preferable
because of the gained efficiency.
Figure 3 gives the conditional power under the log gamma frailty model when adding one
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time as many new subjects in stage 2. The conditional power is similar for  ranging from 0.4
to 0.8. In particular, compared to 22.9 months for  = 0:571, the follow-up time required to
achieve 80% conditional power for  = 0:4; 0:5; 0:7; 0:8 are 26.2, 24.1, 21.0 and 20.0 months,
respectively. Based on this sensitivity analysis, one may choose the more conservative esti-
mate of 26 months.
10 Discussion
We have proposed an adaptive procedure for a survival endpoint to recover power when
the model assumed for design of the trial is suspect. It is worth noting that, as opposed to
Proschan and Hunsberger (1995) who confined the application of conditional power design to
parametric tests, we have generalized the applications to semi-parametric tests for data which
are subject to censoring. Our motivating application was the common situation of unrecog-
nized genetic heterogeneity, known to dilute the power of the log rank test through decreased
precision. This procedure allows for extension of follow-up time, with or without additional ac-
crual of subjects. It also allows for early stopping for futility if the treatment is ineffective. In this
regard, it is widely applicable as it may be tailored to the relative costs of the study.
Effect modification is another plausible mechanism for loss of power. This occurs if the
effect of chemotherapy varies by genetic subtype. This would require including an interaction
term in the proportional hazards frailty model. This may lead to a non-monotone drift function,
making the conditional power procedure inapplicable (i.e., equation (9) cannot be solved).
Thus, alternative adaptive designs are required for this situation.
As for any adaptive procedure, estimates of unknown parameters at early points in the
study may be highly variable. This is especially true for estimation of  as a shared frailty
between event times and for the baseline hazard function. A partial remedy to this problem
would be to re-estimate the frailty parameter at the end of the study and to use it in the final
analysis. The impact of this approach on the overall type I error remains an interesting open
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question.
It must be recognized that this procedure addresses the problem of unexplained hetero-
geneity at the cost of modeling assumptions: the frailty proportional hazards model, including
the baseline hazard function and the frailty distribution, and the shared frailty model. All of
these assumptions certainly call for sensitivity analyses and conservative choices. If genetic
(or other) information becomes available during the course of the trial, it would be desirable to
use that information in the selection of subjects. However, short of new discoveries during the
course of the study that explain heterogeneity, an adaptive procedure such as this to recover
power may be the best approach.
Appendix: Proof of Proposition 2
We prove the weak convergence theorem by using the Cramer-Wold device; we show that any
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Hence, for any two real numbers, c
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By applying the martingale central limit theorem (e.g. Theorem 6.2.1 in Fleming and Harring-
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where L
1
;L
0
1
;L
2
;L
0
2
are mutually independent mean zero normal random variables with vari-
ances
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0
h
0
2
(u)d(u); respectively.
Some algebra may then show that the first 4 terms in (18) converge weakly to a Gaussian
random variable with mean 0 and variance
c
2
1
v(t
1
) + c
2
2
~v(t
1
+ t
2
) + 2c
1
c
2
Z
t
1
0
f1 + rI(u  t
2
)g
 1=2
dv(u);
where
~v(t
1
+ t
2
) =
Z
t
1
+t
2
0
w(u)~(u)d(u):
Hence, by Slutsky’s theorem,
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Table 1: Maximum type I error.
R
max
0.0 0.05 0.1 0.5 1 2 5 10 1

max
0.050 0.059 0.063 0.075 0.082 0.089 0.097 0.102 0.115
Table 2: Adjusted critical value, k, as a function of p and R
max
.
p

R
max
0.1 0.15 0.20 0.25 0.30 0.40 0.50
0.1 1.745 1.754 1.756 1.756 1.756 1.756 1.756
0.5 1.772 1.812 1.829 1.838 1.843 1.847 1.848
1.0 1.773 1.820 1.846 1.862 1.872 1.884 1.889
2.0 1.773 1.821 1.851 1.872 1.888 1.908 1.920
5.0 1.773 1.821 1.852 1.875 1.894 1.921 1.941
10.0 1.773 1.821 1.852 1.875 1.894 1.924 1.947
1 1.773 1.821 1.852 1.875 1.894 1.925 1.951
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Table 3: Type I error rates under possible frailty misspecification as gamma
true frailty distribution
 R
max
1  Æ
y log gamma normal inverse Gaussian
0.3 0.5 0.50 0.050 0.051 0.053
0.80 0.051 0.057 0.049
1.5 0.50 0.049 0.051 0.045
0.80 0.053 0.047 0.047
5.0 0.50 0.046 0.045 0.036
0.80 0.045 0.038 0.041
0.8 0.5 0.50 0.048 0.045 0.051
0.80 0.048 0.052 0.056
1.5 0.50 0.049 0.049 0.047
0.80 0.044 0.050 0.051
5.0 0.50 0.046 0.045 0.040
0.80 0.043 0.045 0.042
y Conditional power threshold for the two-stage procedure.
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Table 4: Simulated unconditional power of conditional power procedure
log gamma frailty analysis no frailty analysis
true model  R
max
1  Æ
y power at t
1
power at t t t1
t
1
power at t
1
power at t t t1
t
1
log 0.3 0.5 0.5 0.837 0.873 0.011 0.817 0.858 0.023
gamma 0.8 0.835 0.894 0.039 0.829 0.893 0.112
1.5 0.5 0.736 0.790 0.037 0.709 0.773 0.053
0.8 0.727 0.818 0.112 0.711 0.801 0.201
5.0 0.5 0.435 0.521 0.216 0.432 0.518 0.238
0.8 0.454 0.577 0.577 0.427 0.563 0.720
0.8 0.5 0.5 0.647 0.698 0.010 0.628 0.695 0.051
0.8 0.649 0.726 0.029 0.628 0.735 0.237
1.5 0.5 0.584 0.649 0.038 0.566 0.638 0.082
0.8 0.591 0.695 0.103 0.566 0.679 0.290
5.0 0.5 0.398 0.480 0.177 0.354 0.444 0.263
0.8 0.377 0.504 0.467 0.359 0.498 0.773
normal 0.3 0.5 0.5 0.858 0.893 0.009 0.848 0.886 0.018
0.8 0.864 0.913 0.032 0.842 0.902 0.098
1.5 0.5 0.762 0.814 0.032 0.754 0.805 0.049
0.8 0.756 0.836 0.103 0.740 0.832 0.166
5.0 0.5 0.470 0.555 0.210 0.452 0.538 0.235
0.8 0.452 0.586 0.568 0.468 0.604 0.682
0.8 0.5 0.5 0.718 0.768 0.008 0.711 0.762 0.036
0.8 0.736 0.799 0.024 0.711 0.802 0.183
1.5 0.5 0.664 0.719 0.029 0.634 0.700 0.067
0.8 0.650 0.744 0.088 0.616 0.733 0.247
5.0 0.5 0.460 0.546 0.167 0.440 0.527 0.242
0.8 0.451 0.585 0.446 0.435 0.568 0.742
inverse 0.3 0.5 0.5 0.735 0.794 0.018 0.705 0.772 0.037
Gaussian 0.8 0.727 0.820 0.063 0.706 0.805 0.184
1.5 0.5 0.582 0.651 0.059 0.541 0.620 0.088
0.8 0.556 0.678 0.182 0.542 0.662 0.294
5.0 0.5 0.285 0.369 0.262 0.279 0.362 0.296
0.8 0.293 0.424 0.659 0.276 0.414 0.884
0.8 0.5 0.5 0.738 0.787 0.007 0.684 0.745 0.044
0.8 0.735 0.799 0.023 0.696 0.797 0.192
1.5 0.5 0.622 0.686 0.034 0.568 0.642 0.079
0.8 0.617 0.714 0.098 0.572 0.688 0.271
5.0 0.5 0.356 0.440 0.184 0.335 0.423 0.269
0.8 0.359 0.494 0.485 0.362 0.492 0.775
y Conditional power threshold for the two-stage procedure.
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Figure 1: Estimated cumulative hazard functions under various frailty distributions. The step
functions in dotted lines represent nonparametric estimates of the cumulative hazard functions.
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(b) Log Gamma
18.5 22.9 28.9
r=2
r=1
r=0.5
r=0
Month
C
on
di
tio
na
l P
ow
er
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
6 12 24 36
(c) Inverse Gaussian
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(d) Positive Stable
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Figure 2: Conditional power based on the optimally weighted log rank statistic for extending
follow-up time (in months) and adding r times as many new subjects, under various frailty
distributions: (a) normal; (b) log gamma; (c) inverse Gaussian; (d) positive stable.
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Figure 3: Conditional power based on the optimally weighted log rank statistic for extending
follow-up time (in months) and adding one time as many new subjects, under the log gamma
frailty distribution and a range of  values.
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